Skip navigation
Use este identificador para citar ou linkar para este item: http://repositorio2.unb.br/jspui/handle/10482/26148
Arquivos associados a este item:
Arquivo TamanhoFormato 
v99n8a16.pdf119,72 kBAdobe PDFVisualizar/Abrir
Título: Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil
Autor(es): Cerqueira, Daniela M
Amorim, Regina MS
Silva, Ruiter R
Camara, Geni NL
Brígido, Marcelo de Macedo
Martins, Cláudia RF
Assunto: human immunodeficiency virus type 1 (HIV-1)
genotyping
antiretroviral resistance
protease
reverse transcriptase
Brazil
Data de publicação: 2004
Editora: Instituto Oswaldo Cruz, Ministério da Saúde
Referência: Mem. Inst. Oswaldo Cruz,v.99,n.8,p.877-882,2004
Resumo: In the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individuals under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping and genotyping. By phylogenetic analysis, 96% of the samples clustered with subtype B and the remaining 4% with HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38% of the samples. Minor mutations were also found at the protease gene: L10I/V (7%), K20M (2%), M36I (11%), L63P (20%), A71T (2%), and V77I (7%). Many mutations associated with reduced susceptibility to nucleoside or non-nucleoside reverse transcriptase inhibitors were detected: M41L (11%), E44D (4%), D67N (11%), T69D (2%), K70R (11%), L74V (2%), L100I (4%), K103N (18%), V118I (9%), Y181C (11%), M184V (18%), G190A (4%), T215Y (4%), and K219E (4%). This study has shown that 84% of the studied population from the Federal District, showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main antiretrovirals to which this population showed resistance were the PI amprenavir (38%), the NNRTIs delavirdine, nevirapine (31%), and efavirenz (24%), and the NRTIs lamivudine (18%), abacavir, and zidovudine (13%).
Unidade Acadêmica: Em processamento
DOI: https://dx.doi.org/10.1590/S0074-02762004000800016
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro completo do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.